Clinical Trial Update: Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector

View source ↗

Summary

This entry reports the completion of a non-interventional study evaluating monthly 300 mg alirocumab (PRALUENT) administered using the SYDNEY auto-injector.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Primary Hypercholesterolaemia and Mixed Dyslipidaemia, Atherosclerotic Cardiovascular Disease | Status: COMPLETED